GlassScriptPhysician profile
Heather Ann Craig
NPI 1073627642
$1,591.76
in general payments reported to CMS, 2019-2025
25 companies · $47.98 in 2025
The $47.98 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $226 · 2021: $215 · 2022: $234 · 2023: $282 · 2024: $169 · 2025: $47.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $307.29 | 2019-2022 | |
| Horizon Therapeutics Plc | $299.76 | 2019-2023 | Krystexxa |
| Pfizer INC. | $221.00 | 2019-2020 | |
| Averitas Pharma INC. | $107.72 | 2023-2024 | Qutenza |
| Paratek Pharmaceuticals, INC. | $82.60 | 2020-2022 | |
| Treace Medical Concepts, INC. | $69.74 | 2022-2025 | |
| Organogenesis INC. | $60.59 | 2021-2023 | Puraply |
| Nabriva Therapeutics, Plc | $47.53 | 2020-2022 | |
| Amgen INC. | $47.06 | 2024-2025 | Krystexxa |
| Bioventus LLC | $46.07 | 2020-2022 | |
| Zyla Life Sciences, INC. | $42.70 | 2019 | |
| Ani Pharmaceuticals, INC. | $36.17 | 2024 | Purified Cortrophin Gel |
| Medtronic, INC. | $31.47 | 2023 | Hawkone, Intellis Adaptivestim |
| Nevro Corp. | $30.73 | 2023 | Senza |
| Integra Lifesciences Corporation | $22.88 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $18.11 | 2024 | |
| Paragon 28, INC. | $17.31 | 2020 | |
| Stryker Corporation | $16.86 | 2023 | Ortholoc 2 Lapifuse |
| Arteriocyte Medical Systems, INC. | $15.49 | 2020 | |
| Kci USA, INC. | $15.17 | 2023 | V.A.C. Dermatac, Activ.A.C., V.A.C. Veraflo |
| Pacira Pharmaceuticals Incorporated | $14.57 | 2019 | |
| Allergan, INC. | $11.66 | 2019 | |
| Aroa Biosurgery Incorporated | $11.08 | 2019 | |
| Sebela Pharmaceuticals INC. | $10.96 | 2019 | |
| Kerecis Limited | $7.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.